Clinical Study

A Randomized, Multicenter, Double-Blind Phase 2 Study Of Palbociclib Plus Cetuximab Versus Cetuximab For The Treatment Of Human Papillomavirus-Negative, Cetuximab-Naive Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck After

Posted Date: Oct 16, 2016

  • Investigator: Trisha Wise-Draper
  • Co-Investigator: Alison Kastl
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to compare the effects of the study drug, palbociclib in combination with cetuximab against placebo in combination with cetuximab. Palbociclib is not approved to treat head and neck cancer, meaning it is an investigational dru


To Be Eligible To Participate In This Study, Participants Must Have Head And Neck Cancer That Cannot Be Treated By Surgery Or Radiation Therapy.


Pfizer A5481044, Cancer, Phase Ii, Head & Neck, Null

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    UC Study Finds Organs from HCV Donors May Be Safe for Liver Transplant

    A UC researcher says livers from HCV patients who test positive for theantibody made to fight the disease may pose a modest risk of infection and beacceptable for transplant